Feline calicivirus VP1-based mRNA vaccine protects cats against FCV challenge

Abstract

References

1. Duclos, A. A., Guzman Ramos, P. J., Mooney, C. T, et al., 2024. Virulent systemic feline calicivirus infection: a case report and first description in Ireland. Ir Vet J. 77, 1.
   

2. Fitz-Patrick, D., McVinnie, D. S., Jackson, L. A., Crowther, G., Geevarughese, A., Cannon, K. D., Garcia, L. M., Pineiro Puebla, Y., Yi, Z., Cunliffe, L., Maniar, A., Zareba, A. M., Ianos, C. A., Gomme, E., Koury, K., Suphaphiphat Allen, P., Anderson, A. S., Gurtman, A., Lindert, K., Pfizer C4781004 Trial Investigators, et al., 2025. Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine. N Engl J Med. 20, 393, 2001-2011.
   

3. Heng, W., Zang, D., Li, R., Qi, R., Jiang, Q., Liu, J., Jia, H., Kang, H., et al., 2025a. A Virulent Systemic Feline Calicivirus Strain Isolated in China Could Produce Broadly Neutralizing Antibodies Against Multiple Strains. Transbound Emerg Dis. 7, 6853477.
   

4. Heng, W., Zang, D., Li, R., Jiang, Q., Liu, J., Jia, H., Kang, H., et al., 2025b. A novel replication-deficient FCV vaccine provides strong immune protection in cats. J Virol. 19, 99(8), e0009325.
   

5. Oda, Y., Kumagai, Y., Kanai, M., Iwama, Y., Okura, I., Minamida, T., Yagi, Y., Kurosawa, T., Greener, B., Zhang, Y., & Walson, J. L., et al., 2024. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect Dis. 24, 351-360.
   

6. Pedersen, N. C., Elliott, J. B., Glasgow, A., Poland, A., Keel, K., et al., 2000. An isolated epizootic of hemorrhagic-like fever in cats caused by a novel and highly virulent strain of feline calicivirus. Vet Microbiol. 73, 281-300.
   

7. Pardi, N., Hogan, M.J., Porter, F.W., Weissman, D., et al.,2019. mrna vaccines -a new era in vaccinology hhs public access author manuscript strategies for optimizing mrna pharmacology. Nat Rev Drug Discov 17, 261-279.
   

8. Schnyder Ghamloush, S., Fanning, S., Essink, B., Eder, F., Snape, M. D., Stoszek, S. K., Guo, R., Dhar, R., Righi, V., Morsy, L., Kapoor, A., El Asmar, L., Shaw, C. A., et al., 2025. Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months. Hum Vaccin Immunother. 21, 2557676.
   

9. Tan, X., Lin, L., Zhang, Q., Li, N., Dong, N., Wang, S., Zhu, W., Luo, M., Pang, S., Xu, Y., Liu, G., Meng, C., et al., First isolation and genomic characterization of a novel inter-genotype recombinant feline calicivirus from domestic cats: Implications for viral evolution. Virol Sin. 2025;40(4):672-675.
   

10. Tian, J., Kang, H., Huang, J., Li, Z.,Qu, L., et al. 2020. Feline calicivirus strain 2280 p30 antagonizes type I interferon-mediated antiviral innate immunity through directly degrading IFNAR1 mRNA. PLOS Pathog 16, e1008944.
    

11. Wei, J., Bystol, K., Alabanza, L., Lim, S., Greig, J., Gopal, P., Reyes Ballista, J. M., Galli, J. D., Warren, C., Swartz, A., David, C., Jeong, U., Gonzalez-Fernandez, E., DeWitt, L. A., Go, G., Lago, A., Radcliffe, S., May Fulton, C. D., Shen, P., Fridman, A., Gaspar, J., Pirrone, A., Wen, Z., O'Donnell, G., Austin, L., McKenney, D., Krosky, P., Liu, Y., Bett, A. J., Zhang L., et al., 2025. Characterization of humoral and cellular immunity induced by mRNA vaccines expressing norovirus VP1 proteins in mice and NHPs. Mol Ther. 12, S1525-0016(25)00751-8.
    

Proportional views